Table IV.
Correlation between Gli expression and NANOG in EOC tissue.
| NANOG expression | |||||
|---|---|---|---|---|---|
| Gli expression | Positive, n (%) | Negative, n (%) | Total, n (%) | P-value | r-value |
| Cytoplasmic Gli1 | 36 (59.0) | 25 (41.0) | 61 (100) | <0.001a | 0.796 |
| Positive | 34 (55.7) | 4 (6.5) | 38 (62.3) | ||
| Negative | 2 (3.3) | 21 (34.4) | 23 (37.7) | ||
| Nuclear Gli1 | 36 (59.0) | 25 (41.0) | 61 (100) | 0.397 | 0.077 |
| Positive | 8 (13.1) | 4 (6.6) | 12 (19.7) | ||
| Negative | 28 (45.9) | 21 (34.4) | 49 (80.3) | ||
| Cytoplasmic Gli2 | 36 (59.0) | 25 (41.0) | 61 (100) | 0.039a | 0.264 |
| Positive | 24 (39.3) | 10 (16.4) | 34 (55.7) | ||
| Negative | 12 (19.7) | 15 (24.6) | 27 (44.3) | ||
| Nuclear Gli2 | 12 (19.7) | 13 (21.3) | 25 (41.0) | 0.145 | 0.187 |
| Positive | 24 (39.3) | 12 (19.7) | 36 (59.0) | ||
| Negative | 36 (59.0) | 25 (41.0) | 61 (100) | ||
The expression of Gli1 and Gli2 in the cytoplasm was significantly positively correlated with that of NANOG in EOC tissues
a
(P<0.05). EOC, epithelial ovarian cancer; NANOG, homeobox protein NANOG.